Longitude Capital
  • ABOUT
  • TEAM
  • PORTFOLIO
  • NEWS
  • CONTACT
  • LP LOGIN
Select Page

AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine

by Seini Moimoi | May 3, 2024 | Portfolio News

Alpha-9 Oncology Announces First Patient Dosed in Phase 1 Study of A9-3202 in Patients with Locally Advanced or Metastatic Melanoma

by Seini Moimoi | May 2, 2024 | Portfolio News

Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich’s Ataxia Cardiomyopathy

by Seini Moimoi | Apr 17, 2024 | Portfolio News

Opna Bio Presents Promising Preclinical Data in Multiple Myeloma with OPN-6602 and in Malignant Mesothelioma with OPN-9840 Showing Significant Tumor Growth Inhibition at the American Association of Cancer Research Annual Meeting

by Seini Moimoi | Apr 10, 2024 | Portfolio News

Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency

by Seini Moimoi | Apr 8, 2024 | Portfolio News

« Older Entries
Next Entries »

Media Contact

Maggie Jamison

mjamison@longitudecapital.com

650-854-5700

  • Facebook
  • X
  • RSS
footer-logo

LP Login

© 2026 Longitude Capital. All rights reserved.
  • Privacy Policy
  • Disclaimer